Insulet Corporation presented at the J.P. Morgan 44th Annual Healthcare Conference, highlighting its leadership in the global diabetes management market. The company shared that its Automated Insulin Delivery (AID) system is the first FDA-cleared solution for both type 1 and type 2 diabetes in the U.S., and is the most requested and prescribed AID system in the country. Insulet reported approximately $2.7 billion in 2025 revenue guidance and over 600,000 active customers across 25 global markets. The company also noted it has driven two-thirds of the AID market growth from 2020 to 2025, achieving a 26% compound annual growth rate (CAGR) during this period and approaching 50% share of global revenue in the segment. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.